CN105534988B - A kind of volume increase of silkworm, prevention and treatment bacterium medicine and its application - Google Patents
A kind of volume increase of silkworm, prevention and treatment bacterium medicine and its application Download PDFInfo
- Publication number
- CN105534988B CN105534988B CN201510968858.1A CN201510968858A CN105534988B CN 105534988 B CN105534988 B CN 105534988B CN 201510968858 A CN201510968858 A CN 201510968858A CN 105534988 B CN105534988 B CN 105534988B
- Authority
- CN
- China
- Prior art keywords
- silkworm
- marbofloxacin
- prevention
- volume increase
- sodium glutamate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000255789 Bombyx mori Species 0.000 title claims abstract description 71
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 241000894006 Bacteria Species 0.000 title abstract description 43
- 230000002265 prevention Effects 0.000 title abstract description 25
- BPFYOAJNDMUVBL-UHFFFAOYSA-N LSM-5799 Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3N(C)COC1=C32 BPFYOAJNDMUVBL-UHFFFAOYSA-N 0.000 claims abstract description 37
- 229960002531 marbofloxacin Drugs 0.000 claims abstract description 37
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims abstract description 34
- 235000013923 monosodium glutamate Nutrition 0.000 claims abstract description 34
- 229940073490 sodium glutamate Drugs 0.000 claims abstract description 34
- 229940079593 drug Drugs 0.000 claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims description 21
- 240000000249 Morus alba Species 0.000 claims description 15
- 235000008708 Morus alba Nutrition 0.000 claims description 15
- 239000007921 spray Substances 0.000 claims description 14
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 17
- 206010040047 Sepsis Diseases 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 13
- 239000012467 final product Substances 0.000 abstract description 13
- 230000000813 microbial effect Effects 0.000 abstract description 11
- 241000193830 Bacillus <bacterium> Species 0.000 abstract description 10
- 208000015181 infectious disease Diseases 0.000 description 9
- 238000011081 inoculation Methods 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- 241001671301 Morus nigra Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 3
- DIOIOSKKIYDRIQ-UHFFFAOYSA-N ciprofloxacin hydrochloride Chemical compound Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 DIOIOSKKIYDRIQ-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 229960001229 ciprofloxacin hydrochloride Drugs 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 229960003760 florfenicol Drugs 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940088515 ciloxan Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- -1 glutamate ion Chemical class 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of volume increase of silkworm, prevention and treatment bacterium medicine and its application, silkworm volume increase, prevention and treatment bacterium medicine, raw materials are as follows: Marbofloxacin, sodium glutamate, water；Above-mentioned raw materials component is mixed to obtain the final product.It is microbial septicemic cemia while having effect of increasing production by soldier to fall bacillus, black chest sepsis bacterium and spirit in prevention and treatment, can greatly improve cocoon yield for preparation silkworm volume increase, preventing and treating bacterial diseases of young drug after the present invention for the first time mixes Marbofloxacin with sodium glutamate.
Description
Technical field
The present invention relates to a kind of volume increase of silkworm, prevention and treatment bacterium medicine and its applications, belong to silkworm disease prevention techniques neck
Domain.
Background technique
China is the world's largest Silk quality producing country and trading country, at present Raw Silk Production account for the 70% of Gross World Product with
On, greig yield accounts for 45% of Gross World Product or more, ranks first in the world.Breed silkworms production in because silkworm disease caused by direct economy
Loss accounts for about the 10~15% of total income, and bacterial disease of domestic silkworm is the Major Diseases in silk cocoon production, and the generation of disease is raw to silk cocoon
Production brings very big loss.
The antibiotic such as Florfenicol, erythromycin or Ciloxan prevention and treatment silkworm bacterium is widely used in the prior art
The generation of disease.But erythromycin is because unstable in the solution, using being subject to certain restrictions；Though Ciprofloxacin Hydrochloride and Florfenicol are right
By soldier, bacillus and the microbial septicemic cemia control efficiency of black chest sepsis are preferable, but to by the microbial septicaemia of spirit, fluorobenzene
Buddhist nun examines almost without control efficiency, and Ciprofloxacin Hydrochloride control efficiency is also undesirable, and the drug used at this stage can only be right
Bacterial disease is prevented and treated, and does not have effect of increasing production.
Marbofloxacin (Marbofloxacin, MBF) is a kind of the 3rd generation carbostyril family antibacterial drugs for being exclusively used in animal,
It can inhibit the topoisomerase needed in bacterium DNA replication and show bactericidal activity, (including hemolytic is not to Gram-negative bacteria
Lever bacterium, haemophilus) effectively, there is good antibacterial effect to gram-positive bacteria and mycoplasma.It has has a broad antifungal spectrum,
The features such as active strong, bioavilability high (close to 100), while also having with other antimicrobials without cross resistance, poison is secondary to be made
With the advantages that small, tissue infiltration power is strong, elimination long half time.
Sodium glutamate (Sodium Glutamate) is a kind of salt formed by sodium ion and glutamate ion, wherein
Glutamic acid is a kind of amino acid, and sodium is a kind of metallic element, belongs to one of the most abundant nonessential amino acid of self-assembling formation.
Summary of the invention
In view of the deficiencies of the prior art, the present invention provides a kind of volume increase of silkworm, prevention and treatment bacterium medicine and its applications.
Technical solution of the present invention is as follows:
Sodium glutamate is in application of the preparation silkworm in volume increase drug.
A kind of silkworm drug for increasing production, preventing and treating bacterial disease, it is parts by weight that raw material components are as follows:
1~64 part of Marbofloxacin, 1~80 part of sodium glutamate；
Above-mentioned raw materials component is mixed to obtain the final product.
Preferred according to the present invention, it is parts by weight that raw material components are as follows:
1~5 part of Marbofloxacin, 2~10 parts of sodium glutamate.The drug falls bacillus and black chest sepsis is microbial loses to by soldier
The prevention and treatment and silk cocoon obvious effect of increasing production of blood disease.
Preferred according to the present invention, it is parts by weight that raw material components are as follows:
8~16 parts of Marbofloxacin, 2~10 parts of sodium glutamate.The drug is to by the microbial septicemic cemia control efficiency of spirit
Significantly.
The above-mentioned silkworm method of administration for the drug for increasing production, preventing and treating bacterial disease, steps are as follows:
(1) silkworm is used to the drug for increasing production, preventing and treating bacterial disease and water 1:(350~3500 in mass ratio) it mixes, preparation sprays
Solution；
(2) will step (1) be obtained sprays solution according to mass ratio 1:(8~12) be sprayed on mulberry leaf, freshen daily food 7~
9 hours, continuously freshens 3~5 days progress preventing and treating bacterial diseases of young of food or four-aged silkworm continuously adds food 3 days, silkworm continuously freshens food 5 from five ages
It carries out volume increase feeding.
The invention has the following beneficial effects:
1, present invention firstly discloses the technical effects that Marbofloxacin and sodium glutamate have volume increase to silkworm；
2, the volume increase of preparation silkworm, prevention and treatment bacterium medicine, Ma Bosha after the present invention mixes Marbofloxacin with sodium glutamate
Star and sodium glutamate, which are used in combination, falls bacillus, black chest sepsis bacterium and spirit is microbial septicemic cemia has increasing simultaneously by soldier in prevention and treatment
Effect is produced, cocoon yield can be greatly improved, and does not influence the drug effect of Marbofloxacin after the two mixing application；
3, this drug has the characteristics that has a broad antifungal spectrum, activity are strong, bioavilability is high (close to 100), at the same also have with
Other antimicrobials without cross resistance, tissue infiltration power is strong, eliminates the advantages that long half time；
4, this product method of administration is simple, is conducive to promote and apply on a large scale.
Specific embodiment
The present invention is further elaborated below with reference to embodiment, but institute's protection scope of the present invention is without being limited thereto.
Marbofloxacin described in embodiment is purchased from Hubei Hai Ya Biotechnology Co., Ltd, and sodium glutamate is grand emerging purchased from Shandong
Bioengineering Co., Ltd.
Embodiment 1
A kind of volume increase of silkworm, prevention and treatment bacterium medicine, raw material components are as follows:
Marbofloxacin 0.15g, sodium glutamate 0.5g；
After Marbofloxacin is mixed with sodium glutamate, it is dissolved in mixing in 1000g water and sprays solution to obtain the final product.
Embodiment 2
A kind of volume increase of silkworm, prevention and treatment bacterium medicine, raw material components are as follows:
Marbofloxacin 0.3g, sodium glutamate 0.6g；
After Marbofloxacin is mixed with sodium glutamate, it is dissolved in mixing in 1500g water and sprays solution to obtain the final product.
Embodiment 3
A kind of volume increase of silkworm, prevention and treatment bacterium medicine, raw material components are as follows:
Marbofloxacin 0.2g, sodium glutamate 0.7g；
After Marbofloxacin is mixed with sodium glutamate, it is dissolved in mixing in 900g water and sprays solution to obtain the final product.
Embodiment 4
A kind of volume increase of silkworm, prevention and treatment bacterium medicine, raw material components are as follows:
Marbofloxacin 0.4g, sodium glutamate 0.8g；
After Marbofloxacin is mixed with sodium glutamate, it is dissolved in mixing in 1000g water and sprays solution to obtain the final product.
Embodiment 5
A kind of volume increase of silkworm, prevention and treatment bacterium medicine, raw material components are as follows:
Marbofloxacin 0.15g, sodium glutamate 0.7g；
After Marbofloxacin is mixed with sodium glutamate, it is dissolved in mixing in 1000g water and sprays solution to obtain the final product.
Embodiment 6
A kind of volume increase of silkworm, prevention and treatment bacterium medicine, raw material components are as follows:
Marbofloxacin 0.4g, sodium glutamate 0.3g；
After Marbofloxacin is mixed with sodium glutamate, it is dissolved in mixing in 1000g water and sprays solution to obtain the final product.
Embodiment 7
A kind of volume increase of silkworm, prevention and treatment bacterium medicine, raw material components are as follows:
Marbofloxacin 0.5g, sodium glutamate 0.3g；
After Marbofloxacin is mixed with sodium glutamate, it is dissolved in mixing in 500g water and sprays solution to obtain the final product.
Embodiment 8
A kind of volume increase of silkworm, prevention and treatment bacterium medicine, raw material components are as follows:
Marbofloxacin 1.3g, sodium glutamate 0.8g；
After Marbofloxacin is mixed with sodium glutamate, it is dissolved in mixing in 1200g water and sprays solution to obtain the final product.
Embodiment 9
A kind of silkworm volume increase drug, raw material components are as follows:
Sodium glutamate 0.5g；
Sodium glutamate is dissolved in mix in 1000g water and sprays solution to obtain the final product.
Embodiment 10
A kind of silkworm prevention and treatment bacterium medicine, raw material components are as follows:
Marbofloxacin 0.4g；
Marbofloxacin is dissolved in mix in 1000g water and sprays solution to obtain the final product.
Embodiment 11
A kind of silkworm prevention and treatment bacterium medicine, raw material components are as follows:
Marbofloxacin 0.5g；
Marbofloxacin is dissolved in mix in 500g water and sprays solution to obtain the final product.
Test example
Following test is done to the effect of silkworm obtained volume increase, prevention and treatment bacterium medicine:
A, to the septicemic cemia controlling experiment as caused by soldier bacillus
Medication group:
Take soldier bacillus (2.5 × 107Cfu/mL), bacterium solution is dipped with disinfection inoculation pin and puncture infection to silkworm from five ages, use
Drug prepared by embodiment 1 to embodiment 6 raises silkworm by 1kg sprinkling 10kg mulberry leaf, adds food daily 8 hours, continuously adds food 5 days,
The remaining time feeds the common supreme cluster of mulberry leaf；
Control group 1:
Take soldier bacillus (2.5 × 107Cfu/mL), bacterium solution is dipped with disinfection inoculation pin and puncture infection to silkworm from five ages, use
Common mulberry leaf raise the supreme cluster of silkworm；
Control group 2:
Take soldier bacillus (2.5 × 107Cfu/mL), bacterium solution is dipped with disinfection inoculation pin and puncture infection to silkworm from five ages, use
Drug prepared by embodiment 10 raises silkworm by 1kg sprinkling 10kg mulberry leaf, adds food daily 8 hours, continuously adds food 5 days, remaining time raises
Feed the common supreme cluster of mulberry leaf；
Control group 3:
Silkworm from healthy five ages is taken, the supreme cluster of common mulberry leaf is fed；
Silkworm survival rate, the 9th day investigation cocoon shell weight of upper cluster are investigated from after connecing bacterium 5 days.
Calculation formula
Table 1
| Silkworm quantity (head) | Silkworm survival rate (%) | |
| Embodiment 1 | 98 | 100 |
| Embodiment 2 | 96 | 100 |
| Embodiment 3 | 101 | 100 |
| Embodiment 4 | 99 | 100 |
| Embodiment 5 | 102 | 100 |
| Embodiment 6 | 98 | 100 |
| Control group 1 | 99 | 0 |
| Control group 2 | 103 | 100 |
| Control group 3 | 102 | 100 |
Table 2
Interpretation of result
Seen from table 1, embodiment 1 has good control efficiency to the septicaemia as caused by soldier bacillus to implementation column 6,
Embodiment 10 also has the same effect, this, which illustrates sodium glutamate not, influences Marbofloxacin to the sepsis as caused by soldier bacillus
The control efficiency of disease；As can be seen from Table 2, embodiment 1 is preventing and treating silkworm septicaemia after using this drug to embodiment 6 well
While cocoon shell weight have different degrees of increase.
B, to by the microbial septicemic cemia controlling experiment of black chest sepsis
Medication group:
Take black chest sepsis bacterium (6.4 × 107Cfu/mL), bacterium solution is dipped with disinfection inoculation pin puncture infection to silkworm from five ages,
The drug prepared with embodiment 1 to embodiment 6 raises silkworm by 1kg sprinkling 10kg mulberry leaf, adds food daily 8 hours, continuously adds food 5 days,
Remaining time feeds the common supreme cluster of mulberry leaf；
Control group 1:
Take black chest sepsis bacterium (6.4 × 107Cfu/mL), bacterium solution is dipped with disinfection inoculation pin puncture infection to silkworm from five ages,
The supreme cluster of silkworm is raised with common mulberry leaf；
Control group 2:
Take black chest sepsis bacterium (6.4 × 107Cfu/mL), bacterium solution is dipped with disinfection inoculation pin puncture infection to silkworm from five ages,
The drug prepared with embodiment 10 raises silkworm by 1kg sprinkling 10kg mulberry leaf, adds food daily 8 hours, continuously adds food 5 days, remaining time
Feed the supreme cluster of common mulberry leaf；
Control group 3:
Silkworm from healthy five ages is taken, the supreme cluster of common mulberry leaf is fed；
Silkworm survival rate, the 9th day investigation cocoon shell weight of upper cluster are investigated from after connecing bacterium 5 days.
Calculation formula:
Table 3
Table 4
| Silkworm quantity (head) | Average cocoon shell weight (gram) | Increase (%) compared with control group 3 | |
| Embodiment 1 | 102 | 0.442 | 2.31 |
| Embodiment 2 | 98 | 0.444 | 2.78 |
| Embodiment 3 | 103 | 0.446 | 3.24 |
| Embodiment 4 | 104 | 0.440 | 1.85 |
| Embodiment 5 | 100 | 0.443 | 2.55 |
| Embodiment 6 | 98 | 0.441 | 2.08 |
| Control group 3 | 102 | 0.432 | 0 |
Interpretation of result
Seen from table 3, embodiment 1 is imitated to by the black microbial septicaemia of chest sepsis with good prevention and treatment to implementation column 6
Fruit, embodiment 10 also have the same effect, this illustrates sodium glutamate not and influence Marbofloxacin to cause to by black chest sepsis bacterium
Septicemic cemia control efficiency；By table 4 as it can be seen that embodiment 1 is to embodiment 6, after using this drug, in prevention and treatment silkworm well
Septicemic cemia while cocoon shell weight has different degrees of increase.
C, to by the microbial septicemic cemia controlling experiment of spirit
Medication group:
Take clever bacterium (1.9 × 108Cfu/mL), bacterium solution is dipped with disinfection inoculation pin and puncture infection to silkworm from five ages, with implementation
Drug prepared by example 7 to embodiment 8 by 1kg sprinkling 10kg mulberry leaf raise silkworm, add daily food 8 hours, continuously add food 5 days, remaining when
Between feed common mulberry leaf；
Control group 1:
Take clever bacterium (1.9 × 108Cfu/mL), bacterium solution is dipped with disinfection inoculation pin and puncture infection to silkworm from five ages, with common
Mulberry leaf raise silkworm；
Control group 2:
Take clever bacterium (1.9 × 108Cfu/mL), bacterium solution is dipped with disinfection inoculation pin and puncture infection to silkworm from five ages, with implementation
Drug prepared by example 11 raises silkworm by 1kg sprinkling 10kg mulberry leaf, adds food daily 8 hours, continuously adds food 5 days, and the feeding of remaining time is general
Logical mulberry leaf；
Silkworm survival rate is investigated from after connecing bacterium 5 days.
Calculation formula
Table 5
| Silkworm quantity (head) | Silkworm survival rate (%) | |
| Embodiment 7 | 99 | 100 |
| Embodiment 8 | 103 | 100 |
| Control group 1 | 102 | 0 |
| Control group 2 | 98 | 100 |
Interpretation of result
By table 5 as it can be seen that embodiment 7 has good control efficiency to by the microbial septicaemia of spirit to implementation column 8, implement
Example 11 also has the same effect, this, which illustrates sodium glutamate not, influences Marbofloxacin to by the microbial septicemic cemia prevention and treatment of spirit
Effect.
D, simulation experiments
Medication group:
10kg mulberry leaf Feeding of healthy four-aged silkworm is sprayed by 1kg with embodiment 1 to 9 drug of embodiment, it is small to add food 8 daily
When, four ages continuously added food 3 days, silkworm continuously adds food 5 days from five ages, remaining time feeds the common supreme cluster of mulberry leaf；
Control group:
With the common supreme cluster of mulberry leaf Feeding of healthy four-aged silkworm；
The 9th day harvesting of cocoon of upper cluster investigates cocoon yield.
Table 6
| Silkworm quantity (head) | Average cocoon shell weight (gram) | Increase (%) compared with control group | |
| Embodiment 1 | 608 | 0.465 | 4.26 |
| Embodiment 2 | 598 | 0.464 | 4.04 |
| Embodiment 3 | 604 | 0.467 | 4.71 |
| Embodiment 4 | 593 | 0.465 | 4.26 |
| Embodiment 5 | 603 | 0.464 | 4.04 |
| Embodiment 6 | 596 | 0.463 | 3.81 |
| Embodiment 7 | 600 | 0.455 | 2.02 |
| Embodiment 8 | 599 | 0.454 | 1.79 |
| Embodiment 9 | 600 | 0.464 | 4.04 |
| Control group | 601 | 0.446 | 0 |
Interpretation of result
It is especially dense in Marbofloxacin by table 6 as it can be seen that all embodiments have preferable effect of increasing production to Silkworm Cocoon Shell amount
For degree between 200~500mg/L, effect of increasing production is the most obvious.
Claims (1)
1. a kind of purposes of composition in preparation silkworm volume increase drug, which is characterized in that the medicine material component is as follows, is
Parts by weight:
1~5 part or 8~16 parts of Marbofloxacin, 2~10 parts of sodium glutamate；And Marbofloxacin application concentration is in 200~500mg/L；
The preparation step is as follows:
(1) silkworm is used to the drug for increasing production, preventing and treating bacterial disease and water 1:(350~3500 in mass ratio) it mixes, preparation sprays solution；
(2) solution will be sprayed according to mass ratio 1:(8~12 made from step (1)) it is sprayed on mulberry leaf, four-aged silkworm continuously adds
Food 3 days, silkworm continuously adds food and carries out volume increase feeding in 5 days from five ages.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510968858.1A CN105534988B (en) | 2015-12-21 | 2015-12-21 | A kind of volume increase of silkworm, prevention and treatment bacterium medicine and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510968858.1A CN105534988B (en) | 2015-12-21 | 2015-12-21 | A kind of volume increase of silkworm, prevention and treatment bacterium medicine and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105534988A CN105534988A (en) | 2016-05-04 |
| CN105534988B true CN105534988B (en) | 2019-04-16 |
Family
ID=55814916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510968858.1A Expired - Fee Related CN105534988B (en) | 2015-12-21 | 2015-12-21 | A kind of volume increase of silkworm, prevention and treatment bacterium medicine and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105534988B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022217475A1 (en) * | 2021-04-13 | 2022-10-20 | 苏州大学 | Method for improving resistance of bombyx mori to phoxim pesticides |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101222927A (en) * | 2005-05-18 | 2008-07-16 | Mpex医药有限公司 | Aerosolized fluoroquinolones and uses thereof |
| WO2011101710A1 (en) * | 2010-02-16 | 2011-08-25 | Wockhardt Research Centre | Efflux pump inhibitors |
| CN102397552A (en) * | 2010-09-10 | 2012-04-04 | 广州自远生物科技有限公司 | Medicinal composite preparation containing quinolones, preparation method thereof and application thereof |
-
2015
- 2015-12-21 CN CN201510968858.1A patent/CN105534988B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101222927A (en) * | 2005-05-18 | 2008-07-16 | Mpex医药有限公司 | Aerosolized fluoroquinolones and uses thereof |
| WO2011101710A1 (en) * | 2010-02-16 | 2011-08-25 | Wockhardt Research Centre | Efflux pump inhibitors |
| CN102397552A (en) * | 2010-09-10 | 2012-04-04 | 广州自远生物科技有限公司 | Medicinal composite preparation containing quinolones, preparation method thereof and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| Nutrition Of The Silkworm, Bombyx Mori-XI. Requirements For Aspartic And Glutamic Acids;TOSHIO ITO et al.;《J. Insect Physiol》;19661231;第12卷;861-869 |
| 家蚕的饲养;伊藤智夫等;《蚕学通讯》;19831231(第2期);1-9 |
| 抗菌剂马波沙星对家蚕细菌病的防治效果;刘文光等;《蚕业科学》;20160312;第42卷(第3期);466-472 |
| 氟喹诺酮类抗菌剂马波沙星的研究进展;陈军等;《中国兽药杂志》;20061231;第40卷(第12期);38-43 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105534988A (en) | 2016-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103125779B (en) | Biological traditional Chinese medicine feed additive for broiler chickens and preparation method thereof | |
| CN104688895B (en) | A kind of Traditional Chinese medicine probiotic compound formulation for preventing and treating chickens respiratory disease | |
| CN105454661A (en) | Pig feed additive for enhancing immunity | |
| CN102836367B (en) | Bacteria-resisting, inflammation-diminishing and itching-relieving traditional Chinese medicine composition and preparation method and application thereof | |
| CN104922586A (en) | Preparing and application of probiotics-fermented traditional Chinese medicinal preparation for preventing and treating coccidiosis in chicken | |
| CN104206789A (en) | Feed additive for preventing cow mastitis and brucellosis and preparation method thereof | |
| CN104322931B (en) | A kind of special feed additive for breeding laying duck | |
| CN104524453B (en) | Can be used for preventing fermentation of Chinese herbal medicine preparation and the application thereof of broiler coli-infection | |
| CN105534988B (en) | A kind of volume increase of silkworm, prevention and treatment bacterium medicine and its application | |
| CN107494936A (en) | A kind of Chinese medicine humic acid feed for treating mastitis for milk cows and preparation method thereof | |
| CN106619767A (en) | Medicine composition for treating dairy cow mastitis as well as preparation method and application thereof | |
| CN102367417A (en) | Traditional Chinese medicine probiotics liquid medium used for fish feed, culturing method and feed additive | |
| CN102367419A (en) | Traditional Chinese medicine probiotics liquid culture medium for poultry feed, culture method and feed additive | |
| CN102000092B (en) | New application of sulfadiazine sodium in preparing medicine for preventing or treating Bombyx mori septicemia | |
| CN110897053B (en) | Fly-expelling traditional Chinese medicine fermented feed for improving egg quality of laying hens and preparation method and application thereof | |
| CN103655987A (en) | Special antibacterial agent for raising river crab | |
| CN109316533B (en) | Fermented traditional Chinese medicine compound preparation for removing endotoxin in pig body and application thereof | |
| CN108815201B (en) | Biological veterinary drug for preventing and treating white scour of piglets and preparation method thereof | |
| CN101966201A (en) | Compound norfloxacin nicotinic soluble powder and preparation method thereof | |
| CN110150486A (en) | A kind of feed addictive for preventing and treating the intestines problems such as milking sow constipation diarrhea | |
| CN104721133B (en) | A kind of terramycin preparation and preparation method | |
| CN109997963A (en) | A kind of sea-buckthorn organic feed | |
| CN103656320A (en) | Oral compound traditional Chinese medicine preparation for preventing poultry chill cold and flu | |
| RU2787768C1 (en) | Means for the prevention and treatment of diarrhea in animals | |
| CN102138884B (en) | Composition applied to washing care products and washing care products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190416 Termination date: 20191221 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |